Tesamorelin vs Tirzepatide

Head-to-head evidence comparison — which supplement is right for you?

Quick answerNo interaction data — ask a pharmacist

Tesamorelin vs Tirzepatide: Tirzepatide has the stronger overall evidence (7.8 vs 5/10); they're alternatives for manage weight — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Tirzepatide Edges Ahead

Tirzepatide wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.

Tesamorelin0 wins

Tirzepatide2 wins

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Tes5.0

Tesamorelin

Too few graded studiesLimited safety

Tir7.8

Tirzepatide

Too few graded studiesLimited safety

Evidence

Evidence Score

5/10

Studies: 30

Meta-analyses: 2

Level: Moderate

Evidence Score

Best7.8/10

Studies: 133

Meta-analyses: 42

Level: Strong

Research findings

Verdict

Too few graded studies

Top outcomes

Visceral fat & body compositionToo few graded studies14
Liver healthToo few graded studies7
Cognitive functionToo few graded studies3

Verdict

Too few graded studies

Top outcomes

Weight managementToo few graded studies80
Glycemic & metabolic controlToo few graded studies53
Heart & blood pressureToo few graded studies20

Shared outcomes (1)

Outcomes where both Tesamorelin and Tirzepatide have evidence — compare verdict strength side-by-side.

Weight managementToo few graded studies14Too few graded studies80

Dosage & timing

Recommended Dosage:

Approved regimen (Egrifta, HIV-associated lipodystrophy only): 2 mg once daily by subcutaneous injection. This is a prescription drug — the dose, indication and monitoring are set by a prescriber. The cognition RCT used a lower 1 mg/day. There is NO validated dose for off-label 'anti-aging' or physique use, and any such use is outside the evidence base.

Warnings

Tesamorelin is a PRESCRIPTION DRUG (Egrifta), NOT a dietary supplement — it should only be obtained and used under a prescription.
Approved ONLY to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. The popular off-label 'anti-aging' / bodybuilding use is NOT what the phase-3 trials studied, and benefit in non-HIV/healthy users is unproven.
It raises IGF-1: theoretical neoplasia/proliferation concern, and it is contraindicated in active malignancy.
Injection-site reactions are common; glucose/insulin can be affected (GH reduces insulin sensitivity) — monitoring is required.
The benefit is entirely treatment-dependent: visceral fat reaccumulates within months of stopping, so there is no durable drug-free effect.
Grey-market 'research-use-only' tesamorelin vials are unregulated — identity, purity, dose and sterility are unverified — and using them is off-label and outside the evidence base.
Contraindicated in pregnancy and in disruption of the hypothalamic-pituitary axis (per the approved label).

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Egrifta / Egrifta SV (prescription, via a clinician)

Recommended Dosage:

Once-weekly subcutaneous injection, started at 2.5 mg and escalated by 2.5 mg every 4 weeks to a maintenance dose of 5, 10, or 15 mg (per the prescribing physician and approved indication)

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.
US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.
Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.
Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.
Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.
A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.
FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.
Not for cosmetic or off-label use without a medical indication and supervision.
May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.
Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Once-weekly subcutaneous injection (Mounjaro / Zepbound)

Safety

Limited safetyTie

Drug Interactions:

Insulin / glucose-lowering drugs (moderate)
Corticosteroids / cortisone-replacement (moderate)
Drugs metabolized by CYP3A (e.g. some statins, certain antiretrovirals) (moderate)

Side Effects:

Injection-site reactions (erythema, pruritus, pain, irritation, swelling, bruising)Arthralgia / joint pain, myalgia, peripheral edema (GH-excess type effects)Increased fasting glucose / reduced insulin sensitivity

Contraindications:

Active malignancy — tesamorelin raises IGF-1, a theoretical proliferative/neoplasia concern; it is contraindicated in active cancer
Pregnancy — contraindicated; GH/IGF-1 stimulation is inappropriate in pregnancy

Limited safetyTie

Drug Interactions:

Oral contraceptives (moderate)
Insulin and sulfonylureas (moderate)
Oral medications generally (moderate)

Side Effects:

NauseaDiarrheaVomiting

Contraindications:

Personal or family history of medullary thyroid carcinoma (MTC) (a contraindication under the US label)
Multiple endocrine neoplasia syndrome type 2 (MEN2) (a contraindication under the US label)

Shared goals

Manage weightTirzepatide

Tesamorelin58/100

Tirzepatide90/100

What you'll notice

🔥 Visceral fat reduction (phase-3 RCTs, HIV lipodystrophy)positive

26-52 weeks

🫁 Liver fat reduction (RCTs in HIV-associated NAFLD)positive

6-12 months

🔄 Benefit reverses on discontinuation (trade-off)trade-off

Within months of stopping

🧠 Cognition: mixed, unapprovedneutral

20-24 weeks

🩸 Strong glycemic controlpositive

Weeks to months

⚖️ Large weight losspositive

Months (dose-escalated over ~20 weeks)

😴 Reduced sleep-apnea severitypositive

Weeks to months

🤢 GI side effects (common)negative

Mostly during titration

Key studies

Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.

J Clin Endocrinol Metab (2010) · Rct · n=806

Pooled analysis of two multicenter, double-blind, placebo-controlled phase-3 RCTs (n=806 ART-treated HIV patients with excess abdominal fat), randomized 2:1 to tesamorelin 2 mg or placebo subcutaneously daily

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.

J Acquir Immune Defic Syndr (2010) · Rct · n=404

12-month phase-3 RCT in 404 ART-treated HIV patients with excess abdominal fat; randomized 2:1 to tesamorelin 2 mg sc daily or placebo, then rerandomized at 6 months

Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation.

AIDS (2008) · Rct · n=410

26-week safety-extension RCT (n=410) of the phase-3 program; tesamorelin 2 mg vs placebo subcutaneously daily, with rerandomization at week 26

All Tesamorelin studies

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.

N Engl J Med (2021) · Rct · n=1879

Open-label 40-week phase-3 head-to-head RCT (SURPASS-2) in 1879 patients with type 2 diabetes, tirzepatide 5/10/15 mg vs semaglutide 1 mg

Tirzepatide Once Weekly for the Treatment of Obesity.

N Engl J Med (2022) · Rct · n=2539

72-week phase-3 double-blind RCT (SURMOUNT-1) in 2539 adults with obesity (without diabetes), tirzepatide 5/10/15 mg vs placebo

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.

N Engl J Med (2025) · Rct · n=751

Phase-3b open-label head-to-head RCT (SURMOUNT-5) in 751 adults with obesity but without diabetes, max-tolerated tirzepatide vs max-tolerated semaglutide

All Tirzepatide studies

Frequently asked questions

Is Tesamorelin better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 5/10) and wins in 2 of 3 categories.

Is Tesamorelin or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 58).

Can I take Tesamorelin and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.

Related comparisons

Iron vs Tesamorelin Tesamorelin vs Whey Protein Semaglutide vs Tesamorelin Semaglutide vs Tirzepatide Liraglutide vs Tirzepatide Thiamine vs Tirzepatide

Still deciding between Tesamorelin and Tirzepatide?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Tesamorelin details Tirzepatide details

Warnings

Tesamorelin is a PRESCRIPTION DRUG (Egrifta), NOT a dietary supplement — it should only be obtained and used under a prescription.

Approved ONLY to reduce excess visceral abdominal fat in HIV-associated lipodystrophy. The popular off-label 'anti-aging' / bodybuilding use is NOT what the phase-3 trials studied, and benefit in non-HIV/healthy users is unproven.

It raises IGF-1: theoretical neoplasia/proliferation concern, and it is contraindicated in active malignancy.

Injection-site reactions are common; glucose/insulin can be affected (GH reduces insulin sensitivity) — monitoring is required.

The benefit is entirely treatment-dependent: visceral fat reaccumulates within months of stopping, so there is no durable drug-free effect.

Grey-market 'research-use-only' tesamorelin vials are unregulated — identity, purity, dose and sterility are unverified — and using them is off-label and outside the evidence base.

Contraindicated in pregnancy and in disruption of the hypothalamic-pituitary axis (per the approved label).

Warnings

PRESCRIPTION DRUG — this is an FDA-approved medication (Mounjaro / Zepbound), not a dietary supplement. Use only under medical supervision for an approved indication.

US FDA labeling includes a boxed warning about thyroid C-cell tumors: tirzepatide caused these tumors in rodents; relevance to humans is uncertain. Under the US label it is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2. For treatment in Germany or Austria, consult the current EU product information for the exact medicine’s locally approved indications, contraindications and warnings; discuss any thyroid history with the prescriber.

Pancreatitis has been reported — discontinue and seek care for severe, persistent abdominal pain; avoid in those with a pancreatitis history.

Gallbladder disease (gallstones, cholecystitis) can occur, partly related to rapid weight loss.

Gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) are common, especially during dose escalation.

A portion of the weight lost is lean (muscle) mass — prioritize adequate protein and resistance exercise.

FDA has warned about compounded and grey-market tirzepatide of unverified identity, purity, and dose — do not source outside a legitimate prescription.

Not for cosmetic or off-label use without a medical indication and supervision.

May reduce the efficacy of oral contraceptives via delayed gastric emptying — use a backup method when starting and after dose increases.

Benefits depend on continued use — randomized withdrawal data show substantial weight regain after stopping.

Frequently asked questions

Is Tesamorelin better than Tirzepatide?

Tirzepatide has a higher evidence score (7.8/10 vs 5/10) and wins in 2 of 3 categories.

Is Tesamorelin or Tirzepatide better for manage weight?

For manage weight, Tirzepatide has a higher relevance score (90 vs 58).

Can I take Tesamorelin and Tirzepatide together?

No documented interaction was found in the data searched. This does not establish that this exact combination is safe.